NRXP
NRX Pharmaceuticals, Inc.
$3.08
+0.65%
2026-05-08
About NRX Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
Key Fundamentals
Forward P/E
6.14
EPS (TTM)
$-1.34
Profit Margin
0.0%
Beta
2.02
Market Cap
$101.5M
Avg Volume (10D)
893K
Recent Breakout Signals
No recent breakout signals detected for NRXP.
Recent Price Range (60 Days)
60D High
$3.29
60D Low
$1.62
Avg Volume
869K
Latest Close
$3.08
Get breakout alerts for NRXP
Sign up for Breakout Scanner to receive daily notifications when NRXP triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
NRX Pharmaceuticals, Inc. (NRXP) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors NRXP daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. NRXP operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.